Cardiff Oncology
Nancy Sherman has served as Vice-President, Clinical Operations since 2023 and prior to that in the role of Sr. Director of Clinical Operations since 2021. She is responsible for having developed the Clinical Operations team at Cardiff and brings over 22 years of extensive Clinical Operations experience. Nancy began her career in 2001 at City of Hope National Medical Center as a Research Associate and was promoted to Sr. CRA, obtaining her CCRP (Certified Clinical Research Professional) Certification. She then spent the next 10 years at Amgen in roles spanning Sr. CTM through Sr. Global Study Manager, working on Phase 1-4 global trials and drug development, many leading to FDA and EMA approvals for drugs such as NPlate, Enbrel and Amgen Biosimilars. Her subsequent Clinical Operations roles of increasing responsibility followed in Early Development at Agensys (Astellas), Director of Program Management at PRA, Global Trial Lead overseeing Janssen Prostate Cancer Programs, GoCAR™ technology trials at Bellicum, and Clinical Program Director, Cardiovascular, Renal & Metabolic at IQVIA Biotech. Nancy obtained her BSN,mHSCI at California State University at San Bernardino with a specialization in patient health education and completed her internship with the American Lung Association.
This person is not in any teams
This person is not in any offices
Cardiff Oncology
Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, improve response to treatment and increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.